Isis Pharmaceuticals and Genzyme said this week that they have submitted their antisense-based cholesterol drug mipomersen for European market approval.
Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
If approved, the companies said the drug would be marketed as Kynamro. A US regulatory submission is expected to be filed later this year.
Isis originally developed mipomersen, and Genzyme acquired the drug's rights in early 2008.